Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 60.16B 8.95B 7.68B 7.21B 6.58B 12.43B 853B 12.49B 85.31B 33.06B 431B 33.6B 32.87B 1,426B P/E 2026 *
45.5x
P/E 2027 * 34.6x
Enterprise Value 55.46B 8.25B 7.08B 6.64B 6.07B 11.45B 787B 11.51B 78.63B 30.47B 397B 30.97B 30.3B 1,314B EV / Sales 2026 *
6.86x
EV / Sales 2027 * 5.77x
Free-Float
61.13%
Yield 2026 *
0.8%
Yield 2027 * 1.06%
Manager TitleAgeSince
Chief Executive Officer 70 1998-10-06
Chief Executive Officer 49 2022-01-18
President - -
Director TitleAgeSince
Director/Board Member 49 2011-07-17
Chairman 70 1998-10-06
Director/Board Member 65 2011-07-17
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8.96B
-3.46%-6.97%+61.83%+115.04% 1,100B
-1.04%-1.00%+53.36%+64.75% 658B
-1.83%-1.60%+25.60%+77.51% 470B
-1.47%+0.24%+42.09%+42.12% 372B
-0.90%+0.05%+25.57%+40.59% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.16%-0.20%+52.46%+72.09% 239B
-0.93%+1.84%-13.11%-52.83% 213B
-0.25%+0.74%+29.58%+93.01% 184B
Average -1.16%+3.01%+31.16%+51.72% 422.54B
Weighted average by Cap. -1.78%+2.21%+40.65%+68.41%

Financials

2026 *2027 *
Net sales 8.09B 1.2B 1.03B 969M 885M 1.67B 115B 1.68B 11.46B 4.44B 57.86B 4.52B 4.42B 192B 9.78B 1.46B 1.25B 1.17B 1.07B 2.02B 139B 2.03B 13.87B 5.38B 70.03B 5.46B 5.35B 232B
Net income 1.36B 202M 174M 163M 149M 281M 19.31B 283M 1.93B 748M 9.74B 760M 744M 32.27B 1.79B 267M 229M 215M 196M 370M 25.43B 372M 2.54B 985M 12.83B 1B 979M 42.49B
Net Debt -4.71B -700M -601M -564M -515M -972M -66.77B -977M -6.67B -2.59B -33.69B -2.63B -2.57B -112B -3.73B -554M -476M -447M -408M -770M -52.87B -773M -5.28B -2.05B -26.67B -2.08B -2.04B -88.34B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-